REPURCHASE OF SHARES IN ASTRAZENECA PLC

 

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 298,733 ordinary shares of AstraZeneca PLC at a price of 2849 pence per share on 20 March 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,273,028,199.

A C N Kemp

Company Secretary

21 March 2012

 

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 299,219 ordinary shares of AstraZeneca PLC at a price of 2844 pence per share on 19 March 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,273,254,069.

A C N Kemp

Company Secretary

20 March 2012

 

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 300,255 ordinary shares of AstraZeneca PLC at a price of 2834 pence per share on 16 March 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,273,509,932.

A C N Kemp

Company Secretary

19 March 2012

 

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 299,014 ordinary shares of AstraZeneca PLC at a price of 2846 pence per share on 15 March 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,273,807,937.

A C N Kemp

Company Secretary

16 March 2012

 

 

Tags:

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe